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Abstract
Background: For a woman with bleeding and threatened abortion, ultrasound scan is
done to confirm the viability of the fetus; however, 10-15% of the embryos are eventually
aborted. Distinguishing between women with good and poor prognosis can be a
helpful approach.
Objective: This study aimed to review the predictive value of Pregnancy-associated
Plasma Protein A (PAPP-A) in relation to the diagnosis of fetal loss.
Materials and Methods: The articles published in multiple databases including Web of
Science, PubMed, MEDLINE, Scopus, and Persian databases such as ISC, Magiran, and
IranMedx were searched for articles published until May 2019. MeSH terms was used
for searching the databases including fetal loss OR pregnancy loss OR abortion OR
miscarriage with the following word using AND; Pregnancy-Associated Plasma Protein-
A OR PAPP-A. Two reviewers extracted data and recorded them in a pre-defined form
and assessed the quality of articles using the Newcastle-Ottawa tool. Meta-analysis
was done using the Comprehensive Meta-Analysis/2.0 software and MetaDisc.
Results: A total number of 16 studies were eligible for the qualitative data synthesis,
out of which 8 studies were included in the meta-analysis. All studies had high and
medium quality. The forest plot analysis showed a sensitivity of 57% (95% CI: 53-63%),
a specificity of 83% (95% CI: 80-85%), a positive likelihood ratio of 3.52 (95% CI: 2.44-
5.07), a negative likelihood ratio of 0.54 (95% CI: 0.37-0.79), and a diagnostic odds ratio
of 6.95 (95% CI: 3.58-13.50).
Conclusion: PAPP-A cannot be recommended on a routine basis for predicting fetal
loss and still further research with a combination of other biomarkers is required.
Key words: Pregnancy-associated plasma protein-A, Fetal loss, Pregnancy,
Systematic review.
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1. Introduction
Fetal loss is defined as the loss of the fetus
before 24 wk of pregnancy, and it occurs in about
10-20% of pregnancies (1). Complex pathological
factors cause fetal loss. However, the main cause
of pathology of fetal loss is still in doubt. For
women with bleeding and threatened abortion,
ultrasound is done to confirm the viability of
the fetus, however, about 10-15% of the embryos
are eventually aborted (2). Once the ultrasound
confirms the viability of the fetus, it is better to
distinguish between women with a good prognosis
and poor ones. Many studies have been done to
find a marker which is able to give the prognosis.
One of these markers is Pregnancy-associated
Plasma Protein A (PAPP-A) (2). This protein was
discovered in the blood of pregnant women in
1974 by Lin and colleagues for the first time
(3), and then in multiple studies its association
with adverse pregnancy outcomes was measured.
Studies have shown that abnormal levels of
maternal serum markers such as PAPP-A have
adverse clinical outcomes in pregnancy, including
fetal growth restriction, diabetes, preeclampsia,
fetal death, placental abruption, miscarriage, and
preterm delivery (4-7). PAPP-A is a kind of protease
that plays a role in binding protein-4 (IGFBP-4) to
insulin-like growth factor. Low levels of PAPP-A
increase protein-4, and lead to decrease in insulin-
like growth factor. Insulin-like growth factor has a
key role in regulating bind of trophoblast to the
decidua and low levels of it leads to abnormal
implantation. As a result, abnormal amounts of
PAPP-A will be a sign of abnormal placental
function and may be associated with complications
of pregnancy including early pregnancy loss (8,
9).
First-trimester screening is done for all pregnant
women at 11-13 + 6 wk, and it is a non-invasive
evaluation to determine the risk of chromosomal
abnormalities, such as Down syndrome (10).
Since this marker is routinely measured in all
women, and it has a relation with pregnancy
outcomes, this cost-effective method can be
used for determining the prognosis of threatened
abortion (1). Identifying patients at risk lead to
increased monitoring of pregnant women who
are at high risk for pregnancy complications (11).
Many studies consider this marker as an important
marker for abortion (12, 13). Several studies
have examined the association between PAPP-A
and fetal loss; however, they reported different
sensitivity, specificity, and critical points and
there is no same agreement among researchers;
therefore, the present study discusses the results
of various studies (1, 2, 8). Also, one limitation of
many studies was the small sample size, which is
controlled through systematic reviews. Systematic
review and meta-analysis are essential tools for
summarizing the evidence in an accurate, correct,
and reliable way. So, researchers felt a need to
conduct a systematic review to get a clear and
uniform result and a comprehensive guide to
clinical use.
This systematic review and meta-analysis aimed
to determine the predictive value of PAPP-A for
fetal loss.
2. Materials and Methods
2.1. Literature search strategy and
study selection
We conducted a comprehensive search
through the following databases for the
articles published until May 2019: Web of
Science, PubMed and PubMed Central,
MEDLINE, EMBASE, Scopus as well as Persian
databases such as ISC (https://isc.gov.ir/en),
Magiran (https://www.magiran.com/), and SID
(https://www.sid.ir/Fa/Journal/). Then, a manual
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search was performed using references and
Google scholar citations in relevant selected
papers. No limitation was applied to the place,
time, and language of the studies. We just had
a time limitation and only the studies published
between1974 and 2019 were included in our
review. Lin and colleagues in 1974 discovered
plasma protein-A in the blood of pregnant women
for the first time, and this was the reason for
choosing the date of 1974 (3). Combinations
of Medical Subject Headings (MeSH) included:
fetal resorption OR fetal loss OR pregnancy
loss OR pregnancy failure OR abortion OR
miscarriage, with the following words by using
AND; Pregnancy-Associated Plasma Protein-A
OR PAPP-A were used in search process. Two
investigators separately searched and selected
relevant articles by screening the titles and
abstracts, and then full papers were retrieved
for having met the inclusion criteria. Articles
were included in our review if (1) they were
original articles with case-control or cohort design,
(2) published after 1974, (3) were conducted
on human population, and (4) assessed the
association between PAPP-A and fetal loss in
singleton pregnancies. We excluded the review
articles, papers, and abstracts presented in the
conferences, letters to the editor, and articles
in newspapers. At the end, a manual search
through articles’ references and citations of
eligible articles was done in order to find articles
that were not obtained by electronic searching.
All papers were stored and organized in EndNote
software.
2.2. Definition of fetal loss
Although different studies have provided various
definitions of fetal loss, it has been described in
this review as loss of the fetus before 24 wk of
pregnancy to cover all definitions (1).
2.3. Data extraction and risk of bias
assessment
Two researchers independently assessed
the eligibility of the articles to extract their
data and checked their qualities. Disparities
during synthesis were discussed with the third
investigator. Data were pulled out in a pre-defined
form designed by the team. This form included
the following information: 1st author, year of
publication, study design, the location of study,
the study period, sample size in each group, the
definition of fetal loss, adjusted variables, and
statistical results of studies for 2 × 2 tables.
Newcastle-Ottawa tool (NOS) was used to
assess the quality for cohort and case-control
studies. This tool consists of three main parts: 1)
selection of participants, 2) comparability, and 3)
ascertainment of exposure or the outcome. Each
study can obtain a maximum of nine stars. We
can allocate “four stars” for part one, “two stars”
for part two, and “three stars” for part three (14).
The face/content validity and inter-rater reliability of
the NOS has been established based on a critical
review of the items by several experts (15). Scores 9,
8, and 7 were assigned to the high-quality papers
6and 5 to the moderate ones, and below 4 were
assigned to the low-quality group.
2.4. Statistical analysis
Statistical analysis was performed using the
Comprehensive Meta-Analysis software (CMA
version 2) and Meta-Disc. Data extracted from
each study were arranged in 2 × 2 contingency
tables. Then, analysis was done using 95%
confidence intervals (CI) for each study. Sensitivity
(true positive rate) and specificity (true negative
rate) were calculated based on the reported
cut-offs in the included studies and represented
them with forest plots. Accordingly, false positive,
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true positive, false negative, and true negative
values were used in the Meta-Disc. A random-
effect model was used to calculate the average
sensitivity, specificity, and other measures across
studies. In order to show the overall accuracy of the
test, SROC curve, the diagnostic odds ratio (DOR),
area under the curve (AUC) and Q* were used.
The likelihood ratios (LR+ and LR−) are about the
percentage of patient and healthy cases that have
similar test results. Summary receiver operating
characteristic curve (SROC) is a useful statistical
tool for assessing diagnostic efficiency of tests and
evaluating the diagnostic value of variables. Since
publication bias is one of the concern for meta-
analysis of diagnostic studies, potential publication
bias for sensitivity and specificity was evaluated
using Egger’s test with CMA. Subgroup analysis
was not performed because of the insufficient
number of studies. P < 0.05 was considered to be
statistically significant.
3. Results
Figure 1 shows the process of literature search
and study selection using PRISMA flowchart. The
database probing identified 420 articles plus
8 more articles, which were found through
searching other sources such as reference
lists and citations of eligible manuscripts.
By reviewing the titles and abstracts, some
manuscripts were identified as duplicates (n =
273), not relating to human subjects, relevant
to histology, related to stillbirth, and having a
clinical trial design (n = 116), for which the full-
texts were not downloaded. After reviewing full
manuscripts of 29 articles in detail, 13 studies
were excluded because of not meeting the
inclusion criteria, enough information, or having
different patient population, for example, one
article was excluded because it evaluated fetal
loss in the IVF population, and not in normal
cases (16). Another article was not eligible
because of assessing the relationship of PAPP-
A and pregnancy loss in ectopic pregnancies
cohort (17). Some studies evaluated stillbirth or
intrauterine death (loss of the fetus after 24 wk
of pregnancy). Overall 16 studies were eligible
and considered relevant to be included in our
systematic review, out of which 8 studies were
further excluded from the meta-analysis because
the data could not be extracted for the 2 × 2
tables.
The characteristics of 16 included studies are
shown in Table I. All selected studies were case-
control and cohort studies. They had a variety
of definitions of fetal loss that ranged from
6 to 24 wk, and also had different matched
variable. The statistical results extracted from each
study have been demonstrated in Table II. In
all articles, the mean or median of PAPP-A was
lower in a group with fetal loss versus group
without fetal loss. None of the studies found
significant relationships between high levels of
PAPP-A and adverse obstetric outcomes. Cut-
offs used in various studies ranged from 0.25 to
0.66.
The quality assessment of selected articles
for evaluating publication bias showed that nine
studies had high quality, six had medium quality,
and no study had poor quality. In total, most
studies had a strong methodology. In selection
domain, some articles did not have adequate case
or control definition. For the comparability domain,
articles that got zero had no matched variables,
and if articles had adjusted variable for either in
study designs or in the statistical analysis were
awarded one star. In the ascertainment of exposure
or assessment of outcome domain, most articles
did not report non-response rate or subjects lost
to follow and also used medical record only or
written self-report for evaluation of exposure (Table
III).
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The results of the meta-analysis for PAPPA
as biochemical markers to predict fetal loss are
summarized in Figures 2-5. We tabulated results
in a 2 × 2 contingency tables and forest plots
created for the sensitivity and specificity of PAPP-
A with their CI. The forest plots analysis showed a
sensitivity of 57% (95% CI: 53-63%) for eight studies
(1, 2, 8, 20, 24, 26, 28, 31), a specificity of 83% (95%
CI: 80-85%) for six studies (1, 2, 8, 20, 28, 31), an LR+
of 3.52 (95% CI: 2.44-5.07), an LR- of 0.54 (95% CI:
0.37-0.79), and a diagnostic odds ratio of 6.95 (95%
CI: 3.58-13.50).
“The SROC curve presents a global summary of
test performance and shows the tradeoff between
specificity and sensitivity. The AUC and an index
Q value are discussed as useful summaries of
the curve. SROC curve is shown in Figure 6.
Our data showed that AUC = 0.85 and Q* =
0.78”.
Funnel plots of pooling sensitivity and specificity
are demonstrated in Figure 7. The asymmetrical
scattering of the points for sensitivity and specificity
suggests possible publication bias which was
confirmed by Egger’s test intercept.
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Valbuena et al. (1) 62.1/ 89.3 0.48 72.3 0.76 67.7 - - 0.35/ 0.98
Ravenswaaij et al. (18) - <0.39 - 0.78 - OR14.53 10.44-20.22 1.11/ -
Karim et al. (19) - ≤0.4 - - - RR 1.7, OR 6.2 - -
Bersinger et al. (20) 74.4/ 76 - 84.2 - - - - -
Hanita et al. (8) 44/ 93 0.66 - 0.66 80/86 - - 0.78/1
Spencer et al. (21) - - - - - OR 3.25 - 0.89/ 1.04
Spencer et al. (22) - ≤0.4 - - - OR 6.2 1.92-20.03 0.4/ 0.98
Gordon et al. (23) 52/87 - - - - OR 2.2 0.3-16.6
Ong et al. (24) 59.3 - - - - - - 0.755/ -
Ruge et al. (2) 25/ 87.6 - - - - - - -
Kaijomaa et al. (25) - 0.3 - - - OR 7.7 - -
Westergaard et al. (26) 89.1 - - - 48.8/ 98.8 RR41.8 - -
Barrett et al. (27) - 0.3 - - - RR 4.7 - 0.84/ 1.03
Ugurlu et al. (28) 51.8/ 86.2 - - - - - - -
Yaron et al. (29) - 0.25 - - - RR 8.76 3.77-20.38 -
Tong et al. (30) - - - - - - - 0.14/ 1.00
AUC: Area under the curve; PPV: Positive predictive value; NPV: Negative predictive value; OR/RR: Odds ratios/relative risks;
CI: C Confidence interval
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Table III. Results of risk of bias based on NOS
Patient selection Patient selection Comparability of
groups
Ascertainment Total NOS
Valbuena et al. (1) 4 2 2 8
Ravenswaaij et al. (18) 3 2 2 7
Karim et al. (19) 4 2 3 9
Bersinger et al. (20) 3 0 2 5
Hanita et al. (8) 4 2 2 8
Spencer et al. (21) 3 2 2 7
Spencer et al. (22) 4 2 3 9
Gordon et al. (23) 3 1 1 5
Ong et al. (24) 3 1 1 5
Ruge et al. (2) 3 0 2 5
Kaijomaa et al. (25) 3 1 2 6
Westergaard et al. (26) 3 0 2 5
Barrett et al. (27) 4 0 3 7
Ugurlu et al. (28) 3 2 3 8
Yaron et al. (29) 4 1 2 7
Tong et al. (30) 2 1 2 5
NOS: Newcastle-Ottawa tool
Records identified through
database searching (n = 410)
Additional records identified 
through other sources (n = 8)
Records after duplicates removed (n = 145)
Records screened by title and abstract (n = 116)
Full-text articles assessed for eligibility (n = 29) Full-text articles excluded due to inclusion
criteria, different patient population, not 
enough information (n = 13) 
Studies included in qualitative synthesis
(Systematic review) (n = 16)
Studies included in quantitative synthesis
(meta-analysis) (n = 8)
Data not expressed as sensitivity and





Records excluded (Articles not relating to 
human subjects, relevant to histology, 
conference abstracts)
Removed (n = 273)
Figure 1. PRIZMA flow diagram for selection of eligible studies.
Figure 2. Forest plot of PAPP-A as biochemical markers for prediction of fetal loss.
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Figure 3. Forest plot of PAPP-A as biochemical markers for prediction of fetal loss.
Figure 4. Forest plot for PAPP-A to predict fetal loss: forest plot showing likelihood ratio of a positive and negative test result with
95% confidence intervals (95% CI).
Figure 5. Diagnostic odds ratio forest plot for PAPP-A to predict fetal loss.
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Figure 6. Summary receiver operating characteristic curve (SROC) for PAPP-A. Each solid circle represents each study in the
meta-analysis.
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Funnel Plot of StandardErrorbyLogit event rate
Figure 7. Funnel plot for the assessment of potential publication bias for sensitivity (A) and specificity (B): by Logit Event Rate and
Egger’s regression intercept.
4. Discussion
Clinicians use diagnostic and predictive tests to
identify the absence or presence of a condition
in patients for the purpose of conducting an
appropriate treatment plan. New diagnostic tools
should be developed for improvements in ease
of performance, speed, cost, patient safety, and
accuracy. Systematic review of diagnostic test
studies provides a summary of the accuracy of
the test based on all available evidence (31).
In women with pain and bleeding in the early
stages of pregnancy, ultrasound alone cannot
provide a definitive result for fetal loss, so it is
necessary to provide an auxiliary test. This review
has highlighted the predictive value of PAPP-A
as biochemical markers to predict fetal loss. It
is clinically important to predict the outcome of
patients with bleeding and pain in the early stage
of pregnancy. The prognostic value of PAPP-A was
investigated in different studies and they reported
different sensitivity and specificity. Our study
combined the results of these studies. The result of
the present study showed low predictive accuracy
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overall. The low predictive value may be described
because of the heterogeneity between studies.
Pillai and colleagues in their systematic review
titled “role of serum biomarkers in the prediction
of outcome in women with threatenedmiscarriage”
found that PAPP-A had a poor and wide sensitivity
ranging from 25 to 64% but a high specificity
ranging from 88 to 94%. Their result about
sensitivity was different from ours because our
findings did not show the wide range and had 57%
sensitivity (53-63), but their specificity was almost
near our result of 83% (80-85). This difference
may be due to the difference in the number of
articles reviewed; their evaluation consisted of just
three articles. Dugoff and colleagues in the FaSTER
trial study showed that although a low level of
PAPP-A alone associated with adverse pregnancy
outcomes, it is a poor predictor of such outcomes
(11).
The SROC curve summarizes the predictive
power to distinguish the samples with the disease
from those without the disease. It is a plot of
sensitivity against specificity. The AUC is obtained
from operating curve (ROC) analysis. The power
considers it good if AUC is closed to 1. In the
present study, the AUC was 0.85 and it shows
that more than 35% of women at risk for fetal loss
can be correctly classified by the predictive model
(Figure 6). As seen in Table II, the results of other
studies are approximately near our results, but our
data showed more powerful differentiation. The
diagnostic odds ratio measures the effectiveness
of a diagnostic test and is less likely to change
with the disease prevalence. It ranges from zero
to infinity. In the present meta-analysis, we found
that the mean DOR of 6.95 indicate a low level of
accuracy.
LRs allow interpretation of the findings for use
in clinical practice by showing how much a given
test results in boost or reduce the probability of
having the condition. It shows how many times
sample with target disorders are more likely to
receive a particular test result than those without
target disorders. Our meta-analysis showed an LR+
of 3.52 (95% CI: 2.44-5.07) and an LR- of 0.54 (95%
CI: 0.37- 0.79). A PLR means low maternal serum
PAPP-A would be three times as likely to be seen
in someone with fetal loss as opposed to someone
without fetal loss. An NLR 0.5 suggests PAPP-A
alone cannot detect patients with fetal loss (Figure
4).
Table I shows that the median or means values
for PAPP-A was lower in fetal loss group. Zhang
et al. reported that the level of PAPP-A mRNA
in basal decidual tissue was decreased in the
group who had a recurrent spontaneous abortion
(32). Suzuki and colleagues said that genetic
factor such as the PAPPA polymorphism may
increase the risk of some types of recurrent
pregnancy loss (RPL) (13). In a group of patients,
Santolaya-Forgas and colleagues declared that
low levels of PAPP-A concentrations can cause
a down-regulation of IGF-II accessibility in fetal
and placental development and that this may
cause spontaneous abortions (33). Dumps and
colleagues suggested that PAPP-A concentrations
decrease in pregnancy failure, and circulating
PAPP-A concentrations in extra uterine pregnancy
(EUP) and abnormal intrauterine pregnancy (abIUP)
were significantly lower in comparison to normal
intrauterine pregnancy (nIUP) (p = 0.02) (17). Bischof
and colleagues demonstrated that PAPP-A levels
were consistently decreased or even undetectable
in established ectopic pregnancies, and also after
IVF when threatened abortions happen (16). The
possible reason for these findings is impaired
placentation because the low level of PAPP-A
in maternal serum is the consequence of poor
placental function that can cause fetal loss (24).
We faced some limitations in our study that
must be considered. One limitation of our
study was substantial heterogeneity among
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studies, and the sources of heterogeneity may be
definition of fetal loss, the study design, adjusted
variable, and gestational age at testing. Also, the
publication bias could be a key concern so that our
results should be interpreted with more caution
(34). The other limitation was the difference in
reporting statistics, which led to exclusion of some
articles from being included in the meta-analysis;
therefore, they made our meta-analysis limited.
The other limitation was our search process. We
did not search for unpublished works (including
unpublished dissertations) and were limited to
the Internet search. So, it is better to include
unpublished papers for future studies. Finally, it
should be noticed that this review was conducted
on studies with singleton pregnancies and should
not be generalized to all pregnant women. Also,
considering the definition of fetal loss under 24 wk
in this study, the results would be irrelevant to the
abortions before 8-9 wk.
5. Conclusion
In conclusion, PAPP-A cannot be recommended
for predicting fetal loss on a routine basis and still
further research is required with a combination of
other biomarkers. Fetal loss may be the result of
a variety of etiologies and not a single disorder;
therefore, a single test cannot predict all causes of
fetal loss. Further studies should be conductedwith
a combination of different tests such as biophysical
and biochemical tests to predict fetal loss with
more precision.
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